Literature DB >> 20721268

[Clinical application of subcutaneous nephrovesical bypass system].

Jun Li1, Xiao-feng Wang.   

Abstract

OBJECTIVE: To evaluated the subcutaneous nephrovesical bypass carried out in patients with ureter obstruction and improve the quality of life of patients with palliative definitive percutaneous nephrostomy.
METHODS: A total of 36 patients with advanced cancer receiving 45 subcutaneous nephrovesical bypass tubes were included in the study. Uronephrosis ranged from 1.8-5.2 cm, serum creatinine 73-760 micromol/L,and glomerular filtration rate (GFR) 19-26 mL/min. The obstruction was proved to be complete by retrograde pyelography. The nephrovesical stents were inserted utilizing percutaneous access to both of the kidney and bladder,and a subcutaneous tunnel was created between the two sites. B-ultrasound, KUB (kidneys, ureters, and bladder), serum creatinine test and GFR were carried out 72 hours after operation.
RESULTS: Urinary diversion operations were successful in the 36 patients, uronephrosis ranged from 0-1.8 cm, all stents were in position, serum creatinine 72-173 micromol/L, GFR 25-40 mL/min after the operation, and the bypass functioned well in 45 stents for 67 to 481 days of the follow-up.
CONCLUSION: Subcutaneous nephrovesical bypass can protect renal function of patients suffering from ureteral obstruction by simple and minimum invasive operation; it can also reduce complications caused by percutaneous nephrostomy and improve the patient's life quality.

Entities:  

Mesh:

Year:  2010        PMID: 20721268

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  2 in total

1.  Long-term results of the treatment of complex ureteral stenosis with extra-anatomic ureteral bypasses.

Authors:  Inés M Laso-García; Javier Lorca-Álvaro; Fernando Arias-Fúnez; David Díaz-Pérez; Marta Santiago-González; Gemma Duque-Ruiz; Francisco J Burgos-Revilla
Journal:  Cent European J Urol       Date:  2020-06-19

2.  Subcutaneous nephrovesical bypass: Treatment for ureteral obstruction in advanced metastatic disease.

Authors:  Yunyan Wang; Gongcheng Wang; Peijin Hou; Haijun Zhuang; Xiaosong Yang; Shuo Gu; Hengbing Wang; Lu Ji; Zongyuan Xu; Junsong Meng
Journal:  Oncol Lett       Date:  2014-11-06       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.